Baseline characteristics of the patients.
| Characteristics | Total (N=50) |
|---|---|
| Age years, median (range) | 66 (31–82) |
| Gender, male, N (%) | 27 (54%) |
| Type of myeloma, N (%) | |
| Ig G | 25 (50%) |
| Ig A | 10 (20%) |
| Ig M | 1 (2%) |
| Ig D | 3 (6%) |
| Light chain disease | 11 (22%) |
| Clonality of Light chain, N (%) | |
| kappa | 33 (66%) |
| Lambda | 17 (34%) |
| Extramedullary disease | |
| Yes, N (%) | 8 (16%) |
| No, N (%) | 42 (84%) |
| Lactate dehydrogenase | |
| >Upper limit of normal | 19 (38%) |
| Normal | 31 (62%) |
| Median renal function (creatinine clearance) before transplant, mL/min, (range) | 58.8 (5.73–110.8) |
| >60, N (%) | 24 (48%) |
| ≥30 to <60, N (%) | 16 (32%) |
| <30, N (%) | 10 (20%) |
| ISS stage at diagnosis | |
| I, N (%) | 6 (12%) |
| II, N (%) | 16 (32%) |
| III, N (%) | 26 (52%) |
| Unknown, N (%) | 2 (4%) |
| Frontline treatment | |
| Bortezomib-melphalan-prednisolone with transplant | 11 (22%) |
| Bortezomib-melphalan-prednisolone without transplant | 36 (72%) |
| Others with transplant | 3 (6%) |
| Eligibility of autologous stem cell transplantation | |
| Eligible, N (%) | 14 (28%) |
| Not-eligible, N (%) | 36 (72%) |
| Best response of frontline treatment | |
| CR or better | 23 (46%) |
| VGPR | 13 (26%) |
| PR | 13 (26%) |
| SD | 1 (2%) |
| Median PFS of frontline treatment, months, median (95% CI) | 23.5 (16.5–25.6) |
| Median OS, months, median (95% CI) | 105.7 (63.7-not available) |
Abbreviations: CI, confidence interval; CR, complete response; OS, Overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; VGPR, very good partial response.
Blood Res 2020;55:159~168 https://doi.org/10.5045/br.2020.2020137
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd